Cargando…

Consistency of recommendations for the diagnosis and treatment of non-small cell lung cancer: a systematic review

BACKGROUND: To systematically assess the consistency of recommendations regarding diagnosis and treatment of non-small cell lung cancer (NSCLC) in clinical practice guidelines (CPGs). METHODS: We systematically searched relevant literature databases and websites to identify CPGs related to NSCLC. We...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Zhe, Yang, Sen, Ma, Yanfang, Zhou, Hanqiong, Wu, Xuan, Han, Jing, Hou, Jiabao, Hao, Lidan, Spicer, Jonathan D., Koh, Young Wha, Provencio, Mariano, Reguart, Noemi, Mitsudomi, Tetsuya, Wang, Qiming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264323/ https://www.ncbi.nlm.nih.gov/pubmed/34295672 http://dx.doi.org/10.21037/tlcr-21-423

Ejemplares similares

EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives
por: Hou, Jiabao, et al.
Publicado: (2022)

Transformation or tumor heterogeneity: Mutations in EGFR, SOX2, TP53, and RB1 persist in the histological rapid conversion from lung adenocarcinoma to small‐cell lung cancer
por: Hao, Lidan, et al.
Publicado: (2023)

Reporting quality of clinical practice guidelines on head and neck cancer: a systematic review
por: Hou, Jiabao, et al.
Publicado: (2022)

Consistency of recommendations for pharmacotherapy of rheumatoid arthritis
por: Hu, Yue, et al.
Publicado: (2022)

Neoadjuvant treatment of stage IIIA-N2 in EGFR-Mutant/ALK-rearranged non-small cell lung cancer
por: Reyes, Roxana, et al.
Publicado: (2021)

Coexistence of a novel CCNY-ALK and ATIC-ALK double-fusion in one patient with ALK-positive NSCLC and response to crizotinib: a case report
por: Wu, Xuan, et al.
Publicado: (2020)

Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer
por: Reguart, Noemí, et al.
Publicado: (2010)

PD-L1 expression testing in non-small cell lung cancer
por: Teixidó, Cristina, et al.
Publicado: (2018)

Salvage surgery after definitive chemoradiotherapy for patients with non-small cell lung cancer
por: Hamada, Akira, et al.
Publicado: (2021)

Emerging therapies for small cell lung cancer
por: Yang, Sen, et al.
Publicado: (2019)

Consistency of Recommendations for Evaluation and Management of Hypertension
por: Alper, Brian S., et al.
Publicado: (2019)

Perioperative Therapy for Non-Small Cell Lung Cancer with Immune Checkpoint Inhibitors
por: Soh, Junichi, et al.
Publicado: (2021)

A quality evaluation of the clinical practice guidelines on breast cancer using the RIGHT checklist
por: Zhou, Hanqiong, et al.
Publicado: (2021)

Evaluation of the reporting quality of guidelines for gastric cancer using the RIGHT checklist
por: Wu, Xuan, et al.
Publicado: (2021)

SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018)
por: Majem, M., et al.
Publicado: (2018)

Consistency of thresholds for eutrophication assessments, examples and recommendations
por: Topcu, D., et al.
Publicado: (2021)

Prognostic factors in potentially resectable stage III non-small cell lung cancer receiving neoadjuvant treatment—a narrative review
por: Calvo, Virginia, et al.
Publicado: (2021)

Development of personalized treatments in lung cancer: focusing on the EGFR mutations and beyond
por: Suda, Kenichi, et al.
Publicado: (2013)

Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy
por: Kobayashi, Yoshihisa, et al.
Publicado: (2016)

Inter-tumor heterogeneity of PD-L1 status: is it important in clinical decision making?
por: Suda, Kenichi, et al.
Publicado: (2020)

Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapy
por: Suda, Kenichi, et al.
Publicado: (2020)

Acquired Resistance Mechanism for MET Tyrosine Kinase Inhibitor
por: Fujino, Toshio, et al.
Publicado: (2021)

Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations
por: Suda, Kenichi, et al.
Publicado: (2021)

Is adagrasib just another sotorasib?—or, should we differentiate their usage according to patients’ clinical presentation?
por: Oya, Yuko, et al.
Publicado: (2023)

Clinical utility of liquid biopsy for the diagnosis and monitoring of EML4-ALK NSCLC patients
por: Sánchez-Herrero, Estela, et al.
Publicado: (2020)

Evaluating the consistency with guideline recommendations for diagnosis and management of idiopathic pulmonary fibrosis in non-academic settings
por: Luckhardt, Tracy R., et al.
Publicado: (2023)

Tyrosine kinase inhibitor combination therapy in first-line treatment of non-small-cell lung cancer: systematic review and network meta-analysis
por: Batson, Sarah, et al.
Publicado: (2017)

Detecting ALK , ROS1, and RET fusions and the METΔex14 splicing variant in liquid biopsies of non‐small‐cell lung cancer patients using RNA‐based techniques
por: Giménez‐Capitán, Ana, et al.
Publicado: (2023)

SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022)
por: García-Campelo, Rosario, et al.
Publicado: (2023)

Correction to: SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022)
por: García-Campelo, Rosario, et al.
Publicado: (2023)

MEK inhibitors for the treatment of non-small cell lung cancer
por: Han, Jing, et al.
Publicado: (2021)

190: PATIENT PERSPECTIVES ON CONSISTENCY OF MEDICAL CARE WITH RECOMMENDED CARE IN ASTHMA
por: Tabrizi, Jafar sadegh, et al.
Publicado: (2017)

Levonorgestrel emergency contraception and bodyweight: are current recommendations consistent with historic data?
por: Kardos, László
Publicado: (2020)

Integrating immune checkpoint inhibitors and targeted therapies in the treatment of early stage non-small cell lung cancer: a narrative review
por: Ortega-Franco, Ana, et al.
Publicado: (2020)

Potential effect of spliceosome inhibition in small cell lung cancer irrespective of the MYC status
por: Suda, Kenichi, et al.
Publicado: (2017)

Apatinib with etoposide capsules as a third- or further-line therapy for extensive-stage small cell lung cancer: an open-label, multicenter, single-arm phase II trial
por: He, Zhen, et al.
Publicado: (2021)

A Screening Method for the ALK Fusion Gene in NSCLC
por: Murakami, Yoshiko, et al.
Publicado: (2012)

Cell Line Models for Acquired Resistance to First-Line Osimertinib in Lung Cancers—Applications and Limitations
por: Ohara, Shuta, et al.
Publicado: (2021)

Utility of the Ba/F3 cell system for exploring on‐target mechanisms of resistance to targeted therapies for lung cancer
por: Koga, Takamasa, et al.
Publicado: (2022)

Surgical therapy for pulmonary metastasis of breast cancer
por: Soh, Junichi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8cmup90hk7p0th3l064v8k8lko